These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 26083155)
1. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. Gutierrez JA; Lawitz EJ; Poordad F J Viral Hepat; 2015 Nov; 22(11):861-70. PubMed ID: 26083155 [TBL] [Abstract][Full Text] [Related]
2. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. McConachie SM; Wilhelm SM; Kale-Pradhan PB Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798 [TBL] [Abstract][Full Text] [Related]
4. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F; J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901 [TBL] [Abstract][Full Text] [Related]
5. [New era in the treatment of chronic hepatitis C - novel direct acting antivirals]. Horváth G; Halász T; Makara M; Hunyady B Orv Hetil; 2015 May; 156(21):841-8. PubMed ID: 26038991 [TBL] [Abstract][Full Text] [Related]
6. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Bailly F; Pradat P; Virlogeux V; Zoulim F Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282 [TBL] [Abstract][Full Text] [Related]
8. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808 [TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. Hong CM; Liu CH; Su TH; Yang HC; Chen PJ; Chen YW; Kao JH; Liu CJ J Microbiol Immunol Infect; 2020 Aug; 53(4):569-577. PubMed ID: 30316726 [TBL] [Abstract][Full Text] [Related]
10. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin. Fedorchenko SV; Martynovych T; Klimenko Z; Yanchenko V; Solianyk I J Viral Hepat; 2020 May; 27(5):548-551. PubMed ID: 31894886 [TBL] [Abstract][Full Text] [Related]
11. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection. Asselah T; Marcellin P Liver Int; 2015 Jan; 35 Suppl 1():56-64. PubMed ID: 25529088 [TBL] [Abstract][Full Text] [Related]
12. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Roncero C; Villegas JL; Martínez-Rebollar M; Buti M Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279 [TBL] [Abstract][Full Text] [Related]
13. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060 [TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Welch NM; Jensen DM Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. Yu ML J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136 [TBL] [Abstract][Full Text] [Related]
19. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Chayama K; Hayes CN Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914 [TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Huang Y; Li MH; Hou M; Xie Y Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):470-479. PubMed ID: 28992878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]